However, even although inhibiting NLRP3 inflammasome activation has been shown to have therapeutic effects in PD animal models, the safety and effectiveness of these potential drugs need to be confirmed in PD patients in clinical trials. This evidence concerns the gene NLRP3 and Parkinson disease.